IMTX · Immatics N.V.
$7.18
+0.42% last session
End-of-day data · close of 2026-10-27
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-3.6
Dividend yield
0.0%
Beta
1.36
Avg volume
1M
Employees
1K
Daily Change %
0.42%
5 Days Change
-5.17%
10 Days Change
6.24%
30 Days Change
-14.58%
60 Days Change
-24.34%
Month to Day Change
-15.28%
Year to Day Change
-31.90%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IMTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-14
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Stifel | Initiates | Buy | $0.00 → $15.00 |
| 2026-05-19 | Chardan Capital | Maintains | Buy | $25.00 |
| 2026-04-28 | TD Cowen | Initiates | Buy | $0.00 |
| 2025-11-24 | Chardan Capital | Maintains | Buy | $25.00 |
| 2025-11-19 | Mizuho | Maintains | Outperform | $19.00 → $23.00 |
| 2025-11-18 | Guggenheim | Maintains | Buy | $16.00 → $19.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-27
- neutral: RSI (14): RSI is 41 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 14.0% below the 50-day MA ($8.35).
- bearish: Price vs 200-day MA: Trading 25.4% below the 200-day MA ($9.62).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.06) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($6.73).
IMTX Price Chart
Loading chart for IMTX…
Fundamentals
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.